Stellar Biotechnologies will form a Paris-based company in a joint venture with Neovacs.
The companies announced the partnership May 11. Neovacs, which is based in Paris, will own 70 percent of the new company, called Neostell. Stellar Biotechnologies will own 30 percent.
Based in Port Hueneme, Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Neovacs was founded in 1993 and is a biotech company focused on treating autoimmune and inflammatory diseases.
• Contact Philip Joens at [email protected]